We are a Vancouver, Canada-based biotech firm focused on developing our innovative lipid nanoparticle (LNP) delivery platform for genetic therapies. We believe our proprietary platform provides a solution to the most critical challenge to effective CRISPR-based gene therapy — the effective and safe in vivo delivery of active gene editing machinery into target tissues.
We have secured the exclusive worldwide license from the University of British Columbia to our foundational technology, and continue to build out our intellectual property and patent portfolio through additional research and development. Currently, we are focused on continued development of our innovative delivery platform for therapeutic gene editing cargoes.
We have undertaken key research activities to support the development of our platform, achieving significant proof of concept data for effective in vivo gene editing. We have approached our studies in a systematic way that enables us to iterate on our foundational system. We are actively using our platform to develop strategies for multiple disease indications, as well as creating new product modifications.
We are excited to be part of the Vancouver biotechnology community, in a city that is rapidly emerging as one of the most vibrant innovation hubs in North America.
Company Details
- Employees
- 13
- Address
- 301 - 980 George Street, Vancouver,bc V6a 0h9,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Vancouver, BC
Incisive Genetics Questions
Incisive Genetics's website is https://www.incisivegenetics.com/
Incisive Genetics's LinkedIn profile is https://ca.linkedin.com/company/incisive-genetics
Incisive Genetics has
13 employees.
View email and phone details for 13
employees at Incisive Genetics.
Incisive Genetics's industry is
Biotechnology Research
Incisive Genetics's top competitors are
Eupraxia Pharmaceuticals Inc.,
Innovative Targeting Solutions Inc.,
Augurex Life Sciences Corp.,
Lux Bio,
Gandeeva Therapeutics,
Xpress Select,
Aspect Biosystems,
Cerecura Nanotherapeutics,
Ubrigene Biosciences Inc.,
Symvivo Corporation.
Incisive Genetics's categories are Biotechnology Research
